Nervgen Pharma Corp (NGEN) Stock Price, Quote & News

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology

Sector: Healthcare

Phone: 778-731-1711

Website: www.nervgen.com

Address:

112-970 Burrard Street, Unit 1290, Vancouver, Canada

kenridge Feb. 23 at 4:26 PM

$NGEN closer to 120MM post dilution, assuming done post FDA meeting (assumes positive news). Approx 100MM fully diluted currently. Another 10-20MM dilution at worst case $5 USD, base case between 8-12 USD

1 · Reply

TH3_PR0F1T Feb. 23 at 4:17 PM

$NGEN How much do you think the dilutions going to be? Did you say $150 million shares in one of your posts?

0 · Reply

Hrumph63 Feb. 23 at 3:25 PM

$NGEN

0 · Reply

TH3_PR0F1T Feb. 21 at 9:50 PM

$NGEN I'm considering buying more but don't want to be too hasty. What impact do you folks on this board think next week's meeting is going to have on the SP? If infact they need to dilute how is this going to impact the share price? Please share your thoughts.

2 · Reply

TH3_PR0F1T Feb. 21 at 1:15 PM

$NGEN when will phase three start? I understand they will need funding for the trial.

1 · Reply

MetalinMaybach Feb. 21 at 12:40 AM

$NGEN Non-important opinion… $4 has been a clear area of support here. Absent any negative news, price action here looks more like consolidation than distribution. As more investors understand the SCI opportunity and regulatory path, I expect sentiment to gradually shift higher. What stands out is the relative strength. In many small-cap biotechs, lack of news typically leads to a slow drift downward. Here, price has been holding its base instead of fading. That suggests a committed shareholder base and limited selling pressure at these levels.

1 · Reply

Sanzoo Feb. 20 at 4:34 PM

$NGEN According to market cap calculations, total shares appear to be around 78 million. Yahoo Finance shows about 78.34 million shares, while Investing.com and Bloomberg show around 79 million. For the Phase 3 trial, approximately how many millions of shares (or funding) might be required? After that, could the total share count increase to around 120 million? I’m just seeking accurate information thnku

4 · Reply

neuroinvestor3 Feb. 20 at 2:44 PM

$NGEN https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications

1 · Reply

CCbank Feb. 19 at 9:28 PM

$NGEN SPARTANS TOMORROW WE GO TO MOON~~!!!!

0 · Reply

Tarquinjones Feb. 19 at 8:58 PM

$NGEN THE DRUG WORKS. ANY AND EVERY PERSON WHO IS INVESTED IN THIS STORY EMOTIONALLY, PERSONALLY AND FINANCIALLY SHOULD START MAKING NOISE FOR THIS STORY TO GET OUT THERE AND GAIN THE MOMENTUM IT NEEDS FOR THE GOOD IT CAN DO FOR PEOPLE ALL OVER THE GLOBE. TELL A FRIEND TO TELL A FRIEND. CALL EVERY REPORTER WHO HAS REPORTED ON NEURALINK, CALL YOUR LOCAL NEWS. CALL EVERYONE.....

1 · Reply

NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 12, 2026, 4:15 PM EST - 11 days ago

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

Feb 11, 2026, 7:00 AM EST - 12 days ago

NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium

2026-02-09T13:05:05.000Z - 14 days ago

NervGen Pharma appoints new president & CEO

2026-02-09T13:00:58.000Z - 14 days ago

NervGen Pharma Appoints Adam Rogers As CEO

2026-02-09T12:28:05.000Z - 14 days ago

NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291

Feb 9, 2026, 7:00 AM EST - 14 days ago

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

2026-02-09T12:00:00.000Z - 14 days ago

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

2026-01-08T13:39:25.000Z - 6 weeks ago

NervGen Pharma Debuts On Nasdaq

Jan 8, 2026, 6:30 AM EST - 6 weeks ago

NervGen Pharma Begins Trading on Nasdaq Today

Dec 17, 2025, 4:18 PM EST - 2 months ago

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Dec 12, 2025, 7:51 PM EST - 2 months ago

NervGen Pharma Announces Proposed Amendment to Warrants

2025-11-24T12:22:10.000Z - 3 months ago

NervGen Pharma GAAP EPS of -$0.06

Nov 24, 2025, 7:05 AM EST - 3 months ago

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Nov 24, 2025, 7:00 AM EST - 3 months ago

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Nov 19, 2025, 4:26 PM EST - 3 months ago

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

2025-11-18T22:06:03.000Z - 3 months ago

NervGen Pharma announces $10M non-brokered private placement

Nov 18, 2025, 4:42 PM EST - 3 months ago

NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Aug 26, 2025, 7:30 AM EDT - 6 months ago

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Aug 21, 2025, 7:30 AM EDT - 6 months ago

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

2025-07-17T11:50:05.000Z - 7 months ago

NervGen Pharma announces CEO transition

Jul 17, 2025, 7:30 AM EDT - 7 months ago

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Jul 7, 2025, 5:30 PM EDT - 8 months ago

NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update

Jul 3, 2025, 4:41 PM EDT - 8 months ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Jul 1, 2025, 7:30 AM EDT - 8 months ago

NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones

Jun 18, 2025, 7:30 AM EDT - 8 months ago

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role

Jun 13, 2025, 9:00 AM EDT - 9 months ago

NervGen Pharma: Risky, Yet Promising With Big Upside

May 21, 2025, 7:30 AM EDT - 9 months ago

NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting

May 16, 2025, 4:30 PM EDT - 10 months ago

NervGen Pharma Grants Stock Options

May 15, 2025, 7:30 AM EDT - 10 months ago

NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

May 7, 2025, 7:30 AM EDT - 10 months ago

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Apr 21, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2025, 5:53 PM EDT - 11 months ago

NervGen Provides Quarterly "At-The-Market" Equity Program Update

Apr 3, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Mar 31, 2025, 7:30 AM EDT - 11 months ago

NervGen Initiates Expanded Access Policy

Mar 25, 2025, 8:30 AM EDT - 11 months ago

NervGen Pharma to Host Virtual Investor Event

Fri, 14 Mar 2025 19:27:00 -0400 - 1 year ago

NervGen Pharma Grants Stock Options

Mar 5, 2025, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Virtual Life Science Investor Forum

Tue, 18 Feb 2025 16:30:00 -0500 - 1 year ago

NervGen Pharma Grants Stock Options

Feb 6, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Jan 29, 2025, 5:00 PM EST - 1 year ago

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 10, 2025, 4:37 AM EST - 1 year ago

NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration

Jan 2, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

2024-12-28T18:00:43.000Z - 1 year ago

Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery +

Dec 25, 2024, 1:25 AM EST - 1 year ago

NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program

2024-11-15T08:33:51.000Z - 1 year ago

NervGen Pharma GAAP EPS of -$0.07

Nov 14, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Nov 7, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

kenridge Feb. 23 at 4:26 PM

1 · Reply

TH3_PR0F1T Feb. 23 at 4:17 PM

$NGEN How much do you think the dilutions going to be? Did you say $150 million shares in one of your posts?

0 · Reply

Hrumph63 Feb. 23 at 3:25 PM

$NGEN

0 · Reply

TH3_PR0F1T Feb. 21 at 9:50 PM

2 · Reply

TH3_PR0F1T Feb. 21 at 1:15 PM

$NGEN when will phase three start? I understand they will need funding for the trial.

1 · Reply

MetalinMaybach Feb. 21 at 12:40 AM

1 · Reply

Sanzoo Feb. 20 at 4:34 PM

4 · Reply

neuroinvestor3 Feb. 20 at 2:44 PM

$NGEN https://www.biospace.com/fda/its-official-fda-will-now-default-to-one-clinical-trial-for-drug-applications

1 · Reply

CCbank Feb. 19 at 9:28 PM

$NGEN SPARTANS TOMORROW WE GO TO MOON~~!!!!

0 · Reply

Tarquinjones Feb. 19 at 8:58 PM

1 · Reply

Tarquinjones Feb. 19 at 8:54 PM

$NGEN

0 · Reply

derekiz Feb. 19 at 5:04 PM

$NGEN This could be helpful. The Seattle Times WASHINGTON — The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies to win approval for new drugs, the latest change from Trump administration officials vowing to speed up the availability of certain medical products. Going forward, the FDA’s “default position” will be to require one study for new drugs and other novel health products, FDA Commissioner Dr. Marty Makary and a top deputy, Dr. Vinay Prasad, wrote in a New England Journal of Medicine piece published Wednesday. The announcement is the latest example of Makary and his team changing longstanding FDA standards and procedures with the stated goal of slashing bureaucracy and accelerating the availability of new medicines.

0 · Reply

NVG291Fan Feb. 19 at 4:04 PM

$NGEN The last two sentences of the post@kenridge made below may be the case - Confirmed by what @Shivanzu heard during the U2FP meeting. On 1/2/25, the company issued a release saying the chronic cohort was fully enrolled… 15 months after announcing the first chronic participant was dosed. On 2/6/25 the company announced the first subacute participant was dosed. With the news it helps the chronic cohort, is safe, with a 2:1 drug/placebo change plus many lessons-learned, maybe subacute enrollment was completed 8 months after the first participant was dosed? Seems possible. If that is the case, then I fully expect the FDA meeting will discuss possible Orphan Drug designation (can only be granted with subacute patients), and therefore the meeting may not occur until a month or two from now. That would still meet what the company said having it “early 2026.”

2 · Reply

aladdinscarpet Feb. 19 at 12:57 AM

$NGEN Man Bites Dog (for the Nth time…) https://share.google/siaYf5ir32aqKoFum

1 · Reply

TH3_PR0F1T Feb. 18 at 9:53 PM

$NGEN Long term this company has massive upside potential!

0 · Reply

NVG291Fan Feb. 18 at 8:40 PM

$NGEN If this helps sub-acute and we go above $5 then I am 100% spamming this board to get us trending on ST and the message out to others. I didn’t spam after the uplist out of courtesy for those of you faithful longs still adding, but it’s time. We need to build a good base for our future fund raise.

1 · Reply

Witzorwitzout1 Feb. 18 at 2:33 PM

$NGEN VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (NGEN) (“NervGen” or the “Company") (TSXV: NGEN) , a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate at multiple upcoming investor conferences. Oppenheimer 36th Annual Healthcare Life Sciences Conference, February 25-26, 2026 Format: Corporate Presentation and 1x1 Investor Meetings Presentation Date: Wednesday, February 25th Time: 12:40 – 1:10 pm ET Location: Virtual TD Cowen 46th Annual Health Care Conference, March 2-4, 2026 Format: Corporate Presentation and 1x1 Investor Meetings Presentation Date: Monday, March 2nd Time: 2:30 – 3:00 pm ET Location: Boston, MA

2 · Reply

Eldorado_Toole Feb. 18 at 2:11 PM

$NGEN I'm buying in the 3.80's, so make my day...

0 · Reply

Lytnup Feb. 18 at 1:14 PM

$NGEN https://nervgen.com/nervgen-pharma-to-participate-at-upcoming-investor-conferences/

0 · Reply

MetalinMaybach Feb. 18 at 3:41 AM

$NGEN Quietly setting up one of the most asymmetric biotech plays out there. SCI is an orphan indication with massive unmet need, strong advocacy pressure, and clear regulatory pathways. Upcoming EOP2 is the real inflection point , that’s where endpoints, trial design, and Accelerated Approval viability get clarified. A moderate float and derisking regulatory milestones means volatility both ways, but the upside here is not priced in yet. Long and patient…. 😑

0 · Reply

xxxxxxx01 Feb. 16 at 7:00 AM

$NGEN Spot on sir this is the only hope for people with progressive forms of ms . I hope they can secure a partnership.

0 · Reply

Lunasicc42 Feb. 16 at 1:58 AM

$NGEN I missed the livestream but I am going to go out on a limb and assume that nothing of consequence was said because no one is talking about it anywhere...

1 · Reply

Market Cap	N/A
Revenue (ttm)	46.92M
Net Income (ttm)	-38.10M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	0.00
Profit Margin	-81.20%
Debt to Equity Ratio	N/A

Volume	775,700
Avg Vol	145,364
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	80%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A